Our top pick for
IGM Biosciences, Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 103 staff and has a market cap (total outstanding shares value) of USD$3 billion.
|52-week range||USD$27.55 - USD$127.11|
|50-day moving average||USD$96.8606|
|200-day moving average||USD$73.5287|
|Wall St. target price||USD$95.3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-71.751|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing IGM Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IGM Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IGM Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, IGM Biosciences shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$-22,649,000|
|Return on assets TTM||-19.33%|
|Return on equity TTM||-32.32%|
|Market capitalisation||USD$3 billion|
TTM: trailing 12 months
There are currently 2.3 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 8.4% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.
IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 188307.4352548). IGM Biosciences's SIR currently stands at 11.97. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 11970 shares are currently held short.
However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 70 shares are currently held short) or 0.2691% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 269 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against IGM Biosciences.
Find out more about how you can short IGM Biosciences stock.
We're not expecting IGM Biosciences to pay a dividend over the next 12 months.
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.